CBAY News and Press, CymaBay Therapeutics Inc. From 01/25/24

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 7.47% on the day to $16.4. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chro...

New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar PR Newswire -- First clinical trial in PBC to show coordinate reductions of IL-...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that its President and Chief Executive Officer, Sujal Shah, will present at ...

2023-12-21 16:23:09 ET More on CymaBay Therapeutics Circling Back On CymaBay Therapeutics CymaBay Therapeutics, Inc. (CBAY) Q3 2023 Earnings Call Transcript CymaBay applies for FDA approval of liver disease drug seladelpar CymaBay spikes ahead of Phase 3 data...

2023-12-15 10:08:22 ET More on CymaBay Therapeutics Circling Back On CymaBay Therapeutics CymaBay Therapeutics, Inc. (CBAY) Q3 2023 Earnings Call Transcript CymaBay spikes ahead of Phase 3 data for lead asset CymaBay Therapeutics Q3 2023 Earnings Preview ...

CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis PR Newswire - NDA is supported by data evaluating seladelpar efficacy and safety in over 500 patients - - Seladelpar is the first New Drug Application from CymaB...

2023-11-27 22:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-27 10:34:03 ET More on Tharimmune, Inc. Financial information for Tharimmune, Inc. For further details see: Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug

2023-11-19 09:52:24 ET Summary Today, we revisit CymaBay Therapeutics, a clinical stage biopharma company focused on developing therapies for liver and chronic diseases. The company's primary product candidate, seladelpar, has shown positive results in treating primary biliary cho...